rs7679916 — SLC2A9

Regulatory upstream variant in the SLC2A9 promoter region; the T allele is associated with modestly elevated serum uric acid in some populations, while the C allele may confer partial protection; independent of the major coding variants at this locus and likely acts through altered GLUT9 transcriptional regulation

See your personal result for SLC2A9

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

SLC2A9 Upstream Regulatory Variant rs7679916 — An Emerging Signal for Uric Acid Regulation

Your kidneys filter roughly 700 mg of uric acid per day, reabsorbing most of it through transporters in the proximal tubule before it reaches the urine. The SLC2A9 gene encodes GLUT911 GLUT9
Glucose Transporter 9, the primary high-capacity urate transporter on the basolateral membrane of proximal tubule cells; it mediates voltage-driven efflux of urate from tubular cells back into the bloodstream, and genetic variation across its approximately 46 kb genomic region accounts for 3–8% of serum urate variance in the population.

rs7679916 lies approximately 2 kilobases upstream of the SLC2A9 transcription start site — in the presumptive promoter region rather than within the gene's coding or intronic sequences. This positions it as a potential regulatory variant affecting how much GLUT9 protein the kidney produces, though the functional mechanism has not been directly demonstrated for this specific variant. It forms part of a high-LD haplotype block (r² > 0.9 among five nearby SNPs) in the upstream region, suggesting these variants are co-inherited and likely tag the same biological signal (Li et al., 2012)22 (Li et al., 2012).

The Mechanism

Because rs7679916 sits upstream of the SLC2A9 coding sequence, it is thought to influence urate handling through transcriptional regulation rather than by changing the GLUT9 protein structure. Variants in presumptive promoter regions can alter transcription factor binding sites: for example, a neighbouring upstream SNP (rs13124007) was found to disrupt a binding site for interferon regulatory factor 1 (IRF-1), potentially reducing SLC2A9 expression. If rs7679916 similarly affects a regulatory element, the T allele may lead to higher GLUT9 expression or activity — increasing urate reabsorption from tubular fluid and raising steady-state serum uric acid levels. However, this mechanistic model is inferred from the genomic context and has not been confirmed by reporter assays or expression quantitative trait locus (eQTL) studies for this specific variant.

The SLC2A9 locus as a whole harbours multiple independent genetic signals for urate levels. rs7679916 represents a potential additional layer to the well-characterised coding signals (rs3733591 Arg265His, rs16890979 Val282Ile) and intronic signals (rs11942223), though whether it is truly independent or in partial LD with these established variants has not been formally tested.

The Evidence

Evidence for rs7679916 specifically is limited. A candidate-gene study of 1,053 hyperuricemia cases and 1,373 normouricemia controls in a Uygur population from Xinjiang, China examined five SLC2A9 SNPs in the upstream region. In the normouricemia subgroup, rs7679916 showed a marginal positive association with serum uric acid concentration (β = 5.77 ± 3.09 mg/dL per allele, P = 0.0626), and the companion upstream variant rs938557 reached significance (β = 11.39, P = 0.0024). Crucially, neither variant showed significant association with hyperuricemia status itself after controlling for age, gender, and BMI (Li et al., 2019)33 (Li et al., 2019).

The broader promoter-region architecture was characterised by Li et al. (2012), who sequenced 21 SNPs in the ~2 kb upstream region in a Chinese male population and identified two SNPs (rs13124007 and rs6850166) significantly associated with gout (ORs of 1.71 and 1.65 respectively) — but rs7679916 itself was not among the significant hits in that study; it was in high LD with several nearby upstream variants (Li et al., 2012)44 (Li et al., 2012).

This evidence base places rs7679916 at an emerging level: a biologically plausible position in the known SLC2A9 regulatory region, marginal association in one population, and no independent replication at the specific variant level.

Practical Actions

SLC2A9 variants as a class — including rs7679916 — point to the same management approach: reducing the purine and fructose inputs that generate uric acid, and supporting the renal machinery that clears it. The key dietary levers with evidence specific to GLUT9 function are:

Purines: Organ meats, shellfish, anchovies, and red meat are the highest-density purine sources. Purine-rich vegetables (spinach, mushrooms, asparagus) have a weaker effect on serum urate than animal purines and are not restricted in major guidelines.

Fructose: High-fructose corn syrup and concentrated fruit juice drive urate synthesis hepatically by depleting ATP and generating AMP, independent of renal transport. SLC2A9-mediated urate transport is facilitated by glucose and fructose — high sugar exposure can amplify urate load on the transporter.

Vitamin C: Vitamin C competitively inhibits urate reabsorption at the renal proximal tubule, providing a genotype-independent uricosuric effect at doses of 200–500 mg/day.

If serum uric acid is borderline or elevated, periodic measurement (every 1–2 years) allows tracking against the clinical threshold of 6.8 mg/dL, above which urate crystallises in joints and soft tissue.

Interactions

With rs11942223 (SLC2A9 intronic signal): rs11942223 is the best-characterised intronic signal at the SLC2A9 locus, explaining up to 6% of urate variance in women. It operates through a regulatory mechanism similar to what rs7679916 may represent. Whether these two upstream/intronic signals are in LD or independent has not been formally assessed — they may partially tag the same haplotype or represent distinct regulatory elements. Carrying risk alleles at both loci would plausibly compound the effect on GLUT9 expression and renal urate clearance.

With rs3733591 (SLC2A9 Arg265His) and rs16890979 (Val282Ile): These coding variants change the GLUT9 protein structure and thus the transporter's intrinsic urate-transport capacity. The upstream variant rs7679916 may act orthogonally — influencing how much transporter is produced rather than how efficiently it functions. Combined effects across regulatory and coding variants at SLC2A9 are additive in their impact on renal urate handling.

With ABCG2 rs2231142 (Q141K): ABCG2 controls intestinal urate secretion (gut efflux pathway). Any renal pathway variant including rs7679916 acts independently of ABCG2. Individuals carrying risk alleles at both rs7679916 and ABCG2 rs2231142 face elevated urate from both the renal reabsorption and intestinal secretion axes simultaneously.

Nutrient Interactions

purines altered_metabolism
fructose altered_metabolism

Genotype Interpretations

What each possible genotype means for this variant.

CC Protective Upstream Haplotype Beneficial

Two protective C alleles — reduced urate-promoting regulatory signal at SLC2A9

You carry two copies of the C allele at rs7679916, placing you in the less common homozygous protective genotype at this locus. Based on gnomAD population data, the C allele frequency is approximately 46% in Europeans, giving a CC frequency of roughly 21% under Hardy-Weinberg equilibrium. In African-ancestry populations the C allele is considerably more common (~79%), so CC is more frequent there.

The evidence for this specific variant is emerging — the T allele showed a marginal positive association with uric acid in a Uygur population study (P ≈ 0.06), suggesting that CC carriers may have a modestly lower uric acid set-point from this regulatory locus. This advantage is small relative to the effect of diet and coding variants at the same gene, and no specific monitoring action is warranted based on this variant alone.

CT Mixed Upstream Signal Intermediate

One T allele — modest upstream regulatory contribution to uric acid

rs7679916 sits approximately 2 kb upstream of the SLC2A9 transcription start site in the presumptive promoter region. Heterozygous CT carriers have one copy of the T allele, which may be associated with modestly higher GLUT9 regulatory activity — potentially increasing renal urate reabsorption slightly. The Uygur population study that first characterised this variant showed a positive beta (β = 5.77 mg/dL per allele, P ≈ 0.06) for the T allele in normouricemic individuals, consistent with a direction of effect toward higher urate, but the evidence is not yet replicated specifically for this rsid.

If serum urate is trending above 5.5 mg/dL and you carry risk alleles at other SLC2A9 or ABCG2 variants, monitoring and dietary optimisation are warranted.

TT Elevated Regulatory Signal High Risk

Two T alleles — higher regulatory drive at the SLC2A9 upstream region

rs7679916 lies in the presumptive promoter region of SLC2A9, approximately 2 kb upstream of the transcription start site. The T allele may alter transcription factor binding or enhancer activity, potentially increasing GLUT9 expression or basal urate reabsorption in the renal proximal tubule. Carrying two T alleles would maximise this putative regulatory effect.

While direct evidence for TT at rs7679916 is limited, the locus context provides important framing: the SLC2A9 locus as a whole explains up to 8% of serum urate variance, and upstream regulatory variants form part of the complex architecture of this signal. The Li et al. (2012) promoter study identified two SNPs in this region significantly associated with gout (OR ~1.7), and rs7679916 is in high LD with variants in that same upstream block.

TT carriers with borderline or elevated serum urate (above 5.5 mg/dL) should consider both dietary optimisation and periodic monitoring, particularly if additional risk alleles at rs3733591, ABCG2 rs2231142, or the intronic signal rs11942223 are also present.